Curis Inc CRIS.OQ reported a quarterly adjusted loss of $1.25 per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of $-2.05. The mean expectation of four analysts for the quarter was for a loss of $1.19 per share. Wall Street expected results to range from $-1.39 to -96 cents per share.
Revenue rose 14.1% to $2.38 million from a year ago; analysts expected $2.60 million.
Curis Inc's reported EPS for the quarter was a loss of $1.25.
Curis Inc shares had risen by 16.7% this quarter and lost 19.9% so far this year.
FORECAST CHANGES
In the last 30 days, one analyst negatively revised an earnings estimate
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Curis Inc is $16.00
This summary was machine generated from LSEG data May 7 at 02:14 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Mar. 31 2025 | -1.19 | -1.25 | Missed |
Dec. 31 2024 | -1.36 | -1.25 | Beat |
Sep. 30 2024 | -1.17 | -1.70 | Missed |
Jun. 30 2024 | -1.67 | -2.03 | Missed |
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.